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Introduction. Dysregulation of G1/S checkpoint of cell cycle has been reported in pituitary adenomas. Our previous finding that Wee1 kinase having role in G2/M checkpoint control is deregulated by microRNAs and other studies also indicated the alteration of G2/M transition in non-functioning pituitary adenomas (NFPAs) however its role and systematic evaluation of G2M genes has not been performed.
Objective. To systematically study the expression of members of the G2/M transition in NFPAs and to investigate if microRNAs can have a role in these changes.
Methods. Totally, 75 NFPA and 14 normal pituitary (NP) tissues were examined. Expression of 28 genes encoding members of the G2M transition was profiled on 35 NFPA and 10 NP samples on TaqMan Low Density Array. Expression of CDC25A and two miRNAs targeting CDC25A were validated by individual quantitative real time PCR using TaqMan assays. Protein expression of CDC25A, CDC25C, CDK1 and phospho-CDK1 (Tyr-15) was investigated on tissue microarray and immunohistochemistry. StaRBase miRFunction analysis was applied to further test the role of miRNAs.
Results Overexpression of CDC25A, CDC25C, Cyclin B, YWHAB, BRCA2 and FANCD2 and underexpression of CDK7, p21, p53, CHEK2, GADD45B transcripts were observed in NFPA compared to normal tissues. CDC25A and both the total and the phospho-CDK1 proteins were overexpressed in adenoma tissues. CDC25A correlated with nuclear localized CDK1 (nCDK1) and with tumor size and nCDK1 with Ki-67 proliferation index. MiR-424 and miR-503 targeting CDC25A were downregulated in NFPA and negatively correlated with CDC25A expression.




Pituitary adenomas represent the second most frequent (15.3%) central nervous system tumors following meningiomas [1]. Although these tumors are mostly benign and indolent they may cause significant morbidity due to consequences of hormonal dysfunction and mass effects. Based on recent data their overall prevalence rates (estimated by autopsy and radiology findings) varies from 10 to 22%, but clinically relevant pituitary adenomas appear more rarely (1:1388) [2-4].
Although the familial well-defined hereditary tumor syndromes such as multiple endocrine neoplasia type 1 (MEN1), Carney complex and rare cases of familiar isolated pituitary adenomas (FIPA) are linked to a dysfunction of a single gene (MEN1, PRKAR1A, AIP), the molecular mechanisms leading to sporadic pituitary tumor development are still largely unknown particularly for hormonally inactive, non-functioning adenomas (NFPA).
Because pituitary adenomas often remain responsive to normal trophic influences [5], they sometimes grow extremely slowly. Mutations of tumor suppressor genes or activation of oncogenes that are frequent in other tumors are rare in these adenomas [6].
The cell cycle progression is controlled by the expression and elimination of active cyclin-cyclin-dependent kinases (CDK) complexes. With respect to the pituitary, dysregulation of cell cycle has been demonstrated mainly through alteration of genes regulating the G1/S checkpoint [7]. Underexpression of cyclin-dependent inhibitors (CDKIs) (p14, p15, p16, p18, p21, p27), retinoblastoma protein [8-9], and MEG3a (a strong cell growth suppressor that transactivates p53 thereby regulates cell cycle progression) have been found downregulated through hypermethylation in pituitary adenomas [10-11]. Cyclin D and Cyclin E which are involved in G0-G1 phases of cell cycle were overexpressed in 49% (Cyclin D1) and 37% (Cyclin E) of these adenomas as compared to normal tissues [11-14]. Cyclin A labeling index (LI) was also significantly higher in pituitary adenomas [14].
Our group previously identified that Wee1 kinase, a nuclear protein that delays mitosis was downregulated in growth hormone (GH) producing adenomas and NFPAs compared to normal pituitary [15]. Wee1 phosphorylates CDK1 and inhibits its kinase activity, thereby preventing entry into the mitosis at the G2/M checkpoint. The tumor suppressor function of Wee1 is reinforced by its underexpression in colon tumors moreover, its dowregulation showed correlation with prognosis, recurrence and proliferation index in non-small-cell lung cancer [16-17]. Additionally, bioinformatics and network analysis of pituitary proteomic data [18] identified dysregulation of cell cycle at the G2/M DNA damage checkpoint, mitochondrial dysfunction, oxidative stress and MAPK signaling pathways significantly altered in pituitary adenomas. Other clues for involvement of G2/M transition and its promising targeting in pituitary tumors came from the study of Yu et al [19]. They showed that proteosome inhibitors induced apoptosis in pituitary adenoma but not in normal pituitary cells in rat through blocking the cell cycle at G2/M transition [19]. Furthermore, it was observed that a bioflavonoid was able to inhibit growth through G2/M arrest and inducing apoptosis in lung cancer cell line [20].




Pituitary adenoma tissues were removed by transsphenoideal surgery at the Hungarian National Institute of Neurosurgery. Totally, 75 NFPAs (33 females, 42 males, mean age±SD: 58.7±13.3) and 14 normal pituitary tissue specimens were used for analysis (Table 1). All adenoma samples were gathered with the permission of the local committee on human research, after written informed consent of each patient. The research protocol was approved by the Scientific and Research Ethics Committee of the Medical Research Council (nr: ad.4457/20121/EKU). RNA extracted from 35 NFPAs and 10 NP fresh frozen specimens were used for initial screening with TaqMan Array, RNA extracted from 23 NFPAs and 10 NP were used for RT-qPCR validation. 

Table 1. Characteristics of pituitary tumor samples and hormone values of patients.

















































































NA: not available, -: not measured, *: recurrent adenoma.

The clinical diagnosis of NFPAs was based on hormone levels measured in serum obtained from patients and on results of immunohistochemistry analysis for SF1 transcription factor specific for gonadotrope origin and six anterior lobe hormones following WHO classification [21]. Immunostaining of Ki-67 proliferation marker in each sample was also performed. All immunohistochemical studies were performed at the 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. Ten normal pituitary samples for mRNA expression analysis were obtained by autopsy within 6 h of death from patients with no evidence of any endocrine disease (University Clinical Centre, Belgrade, Serbia). Patient characteristics are presented in Table 1. For tissue microarray (TMA) healthy pituitary tissues surrounding 4 adenomas (one NFPA and 3 hormone producing adenoma) were used as normal control.

RNA isolation
Removed specimens were stabilized in RNA later (Life Technologies, Grand Island, NY, USA) and then stored at -80 oC until use. Total RNA was extracted using miRNeasy Mini Kit (Qiagen Inc., Chatsworth, CA). RNA integrity and concentration were measured using Agilent Bioanalyzer 2100 System (Agilent Tech Inc., Santa Clara, USA).

Gene expression profiling using custom TaqMan Low Density Array microfluidic card
Expression profile of 40 genes was analyzed in 29 NFPA and 10 normal pituitary samples using custom made TaqMan Low Density Array (TLDA) (Life Technologies, Grand Island, NY, USA) including assays for POU1F1 and members of the G2/M transition. All assays are summarized in Suppl. Table 1. All procedures were performed according to the manufacturer’s instructions. Briefly, reverse transcription of 1 μg of total RNA was performed using the Superscript III First Strand Synthesis Kit (Life Technologies). Then 5 μl undiluted RT product, 55 μl TaqMan Universal PCR Master Mix and 50 μl DEPC treated water were loaded into each channel of TLDA card in a 100 μl final volume. The mRNA expression was determined with RT-qPCR using the 7900 Fast Real-Time PCR System (Life Technologies).

Real-time quantification of miRNAs and CDC25A and CDC25C
RT-qPCR was executed as previously described  ADDIN REFMGR.CITE (15;22). Reverse transcription was performed using Superscript III First Strand Synthesis Kit (Life Technologies) or miRNA specific stem-loop RT primer using TaqMan MicroRNA Reverse Transcription Kit (P/N: 4366596) according to protocols provided by the supplier. For the qPCR specific Taqman probes and TaqMan Universal PCR Master Mix were used (Life Technologies). Reactions were run in triplicates in 384-well plate on 7900 HT RealTime PCR System (Life Technologies). The following Gene Expression and Individual MicroRNA Assays from Applied Biosystems were used: CDC25C (Hs00156411_m1), CDC25A (Hs00947994_m1), CDK1 (Hs00938777_m1), ACTB (Hs99999903_m1), GAPDH (Hs99999905_m1); and hsa-miR-424 (Assay ID: 001149), hsa-miR-503 (Assay ID: 001048), U6 snRNA (Assay ID: 001973), RNU48 (Assay ID: 001006), RNU44 (Assay ID: 001094). Gene expression data were normalized with the use of geometric mean of ACTB and GAPDH in the case of mRNA and geometric mean of RNU44, RNU48 and U6 snRNA in the case of miRNAs as previously those were identified to be stable endogenous controls in pituitary [22]. Expression level was calculated by the ddCt method, and fold changes were obtained using the formula 2-ddCt.

Tissue microarray (TMA), immunohistochemistry, digital microscopy, scoring and image analysis
Formalin-fixed, paraffin-embedded tissues from 70 pituitary samples were selected based on haematoxylin and eosin (H&E) staining and immunostaining for the six anterior lobe hormones. Two-mm cores were collected into a 7x10-sample TMA recipient block. Excel files containing clinicopathological data of 70 samples from 70 patients were linked to recipient block positions using a computer-driven automated instrument TMA-Master (3DHistech Ltd, Budapest, Hungary). 
Following antigen retrieval by boiling (15 min, 0.1 mM pH 6 citrate-buffer) and endogenous peroxidase block (1% H2O2), tissues were stained with CDC25A mouse monoclonal (Santa Cruz Biotechnology, sc-56264; dilution: 1:100), CDC25C (C20) rabbit polyclonal (Santa Cruz Biotechnology, sc-327; dilution: 1:100 ), total CDC2 mouse monoclonal (Cell Signaling, Beverly, USA, #9116; dilution: 1:40) and phospho-CDC2 (p-Tyr15) rabbit polyclonal (NBP1-19966, Novus Biologicals, dilution: 1:40) primary antibodies overnight, and biotin conjugated goat anti-rabbit (DakoE0432) and anti-mouse (DakoE0433) secondary antibodies for 60 min. After the addition of ABC reagent for amplification (Vectastain Elute ABC Kit, PK-6101), diaminobenzidine (DAB) chromogen was used for detection. Optimization for each antibody was executed using positive (breast cancer and normal pituitary) and negative controls.
Immunostained TMA slides were analyzed following full-slide digitalization with the Panoramic Scan and the database-linked TMA Modul software (both 3DHISTECH Kft, Budapest, Hungary). Quantitation was performed using a 12-score system considering staining intensity and frequency of stained cells. Briefly, weak staining was scored by 1-4, moderate staining was scored by 5-8 and strong staining by 9-12 according to the number of positive cells (<10%, 10-40%, 40-80% and >80%) using TMA Modul Software (3DHISTECH Kft, Budapest, Hungary). Scoring was performed by two independent assessors and average scores were used for statistical analysis. Each score was normalized for the average score of normal samples. 

Identification of miRNAs targeting CDC25A and CDC25C by in silico target prediction
For target prediction we used four computational target prediction algorithms: microrna.org (http://www.microrna.org/microrna/home.do (​http:​/​​/​www.microrna.org​/​microrna​/​home.do​)), Targetscan 4.0 (http://www.targetscan.org (​http:​/​​/​www.targetscan.org​/​​)), MicroCosm (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/ (​http:​/​​/​www.ebi.ac.uk​/​enright-srv​/​microcosm​/​htdocs​/​targets​/​v5​/​​)) and miRWalk (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/index.html (​http:​/​​/​www.ma.uni-heidelberg.de​/​apps​/​zmf​/​mirwalk​/​index.html​))

Statistical analysis 
After data normalization using geometric mean of endogenous controls, gene expression levels in NFPA were compared to those found in normal pituitary tissues using T-test or Mann-Whitney U test depending on the results of Shapiro-Wilks normality test. Statistical analysis was performed using Statistica 7.0 software (StatSoft Inc., Tulsa, USA). For correlation analysis between gene expressions and expression of miRNAs and CDC25A and CDC25C or tumor size Pearson’s or Spearman rank correlation tests were used. Nonparametric Kruskal-Wallis ANOVA and Spearman rank correlation were used as statistical methods for analyzing TMA results regarding the discrete variables. A value of p<0.05 was considered to be significant. Tumor size were calculated tumor width x length x height in mm using three direction MRI scans.

Results
1.	Expression of genes encoding members of G2/M transition in NFPAs
First we tested our NFPA samples by analyzing the expression of GH, PRL, FSH, LH, POMC and POU1F1 (Pit-1) genes. Adenomas expressing POU1F1 transcription factor mRNA were excluded indicating contamination by nontumorous elements [21, 23-24]. All adenomas showed decreased expression of GH, PRL and POMC on mRNA level compared to healthy control samples (Suppl. Figure 1).
Expression analysis of 28 genes involved mainly in the G2/M transition of the cell cycle was performed by a custom made TLDA card (TaqMan Low Density Array) on 29 NFPA and 10 normal pituitary tissue specimens. We observed that CDC25A, CDC25C, Cyclin B, YWHAB, BRCA2 and FANCD2 were significantly overexpressed while CDK7, p21, p53, CHEK2, GADD45B were underexpressed in NFPA tissue specimens compared to normal pituitary (Figure 1A). We also identified several correlations among the measured genes which are illustrated on Suppl. Figure 2, and showed that CDC25A mRNA expression level is correlated with Cyclin B as well as CDC25C with CDK1 in NFPAs but not in normal pituitary tissue. For validation of the TLDA results expression of CDC25A and CDC25C using individual TaqMan assays was measured on 33 pituitary samples, and the results were similar to those obtained with the TLDA card experiment (Figure 1B). 

Figure 1. Panel A: Differently expressed genes encoding members of the G2/M transition of cell cycle in NFPA samples reaching significance compared to normal pituitary. Significantly different expression of CDC25A (fold change: 2.1; p=0.002), CDC25C (fold change: 2.6, p=0.002), CCNB1 (fold change: 1.6; p=0.003), CDK7 (fold change: -1.6; p<0.001), CHEK2 (fold change: -1.5; p=0.004), TP53 (fold change: -1.5; p=0.013), GADD45B (fold change: -9.1 ; p=0.008), CDKN1A (p21) (fold change: -6.5; p<0.001), YWHAB (fold change: 1.4; p=0.023), BRCA2 (fold change: 2.8; p<0.001), and FANCD2 (fold change: 1.8; p=0.001) was detected by Taqman Low Density Array Card. Panel B: Overexpression of CDC25A and CDC25C was validated by individual Taqman assays on real time-quantitative PCR. CDC25A: fold change: 2.8, p=0.001; CDC25C: fold change: 7, p<0.001)


2.	Increased expression of CDC25A and CDK1 at protein level in NFPAs 
CDC25A, CDC25C, total CDK1 and p-CDK1 were evaluated on TMA after staining optimization (Figure 2). CDC25A, total CDK1 and phospho-CDK1 (pCDK1: inactive form) were significantly overexpressed in NFPA samples compared to normal tissues (Figure 3). However, the ratio of pCDK1/CDK1 was similar in the two groups of samples suggesting no change in activity rate only in total amount of protein. In total, CDC25A was overexpressed in 76% (35/46) of NFPAs (the expression level of CDC25A was higher in all of these adenomas than the highest expression detected in normal tissues). CDC25C was overexpressed in 45.6% (21/46) of NFPAs, but globally the expression of CDC25C at protein level did not differ significantly between NFPA and normal tissues. Elevated level of total CDK1 and pCDK1 were detected in 82.6% (38/46) and 63% (29/46) of NFPAs, respectively. The nuclear CDK1 (nCDK1), staining score did not differ significantly between NFPA and normal tissue.

Figure 2. CDC25A, CDC25C, CDK1 and p-CDK1 staining in positive, negative controls and in pituitary
Figure 3. Expression of CDC25A, CDC25C, CDK1 and p-CDK1 in normal pituitary and NFPA. Representative immunochemistry (Panel A) and semi-quantitative immunohistochemistry scores of CDC25A, CDC25C, CDK1 and pCDK1 in NFPAs and normal pituitary tissues (NP). Scale markers in left upper corners represent 100 µm. Mean and SE are indicated by the ranges. *, p<0.05; **, p=0.05. (Panel B).

Correlation between the expression of CDC25A and CDC25C proteins was observed in NFPAs (p=0.001) (Figure 4A). CDC25A at protein level correlated with tumor size (Figure 4B) and with nCDK1 (Figure 4C). Nuclear CDK1 the active form of the kinase, showed a positive correlation (p=0.0003) with the Ki-67 proliferation index (Figure 4D). Expressions of CDC25C failed to correlate with the nCDK1 scores, tumor size. Neither CDC25A nor CDC25C staining correlated with Ki67 (data not shown).

Figure 4. Correlation between the expression of CDC25A, CDC25C proteins, nuclear CDK1, Ki67 and tumor size represented by immunostaining scores. Significant correlation was observed between CDC25A and tumor size (R=0.66, p=0.01; Panel C), CDC25A and nCDK1 (R=0.34 and p= 0.01; Panel C) and Ki-67 and nCDK1 (R=0.53; p=0.0003; Panel E). No significant associations were observed CDC25C and tumor size (R=0.02, p=0.93; Panel B) and CDC25C and nCDK1 (R=0.28 and p=0.054; Panel D). Spearman correlation analysis was performed and p <0.05 was accepted as statistically significant.


3.	miR-424 and miR-503 are underexpressed in NFPA samples 
In order to test whether copy number variation of chromosomal localizations of CDC25A and CDC25C (3p21, 5q31) has been detected we reviewed the data of five different comparative genome hybridization (CGH) studies performed on pituitary adenoma samples, but chromosomal gain for these loci was detected only in a small proportion of NFPAs [25-29] suggesting that no gene amplification occurs in the majority of samples. Other observations showed a discordant expression of CDC25 phosphatases at mRNA transcript and protein levels. It is therefore possible that dysregulation of CDC25s may occur at transcriptional, posttranscriptional or posttranslational stages [30]. Additionally, CDC25A has been described as a miRNA target as well [31], it is posttranscriptionally modulated by hsa-miR-424 and hsa-miR-503. Furthermore, expression of these miRNAs has been previously found to correlate with pituitary adenoma size [22]. Thus, we validated our previous miRNA array results by RT-qPCR using individual TaqMan assays. Both miRNAs were significantly underexpressed in pituitary tumors compared to normal tissues (Figure 5A) and both correlated with tumor size (Pearson Rank correlation: miR-424, R: -0.890, p < 0.001; miR-503, R: -0.951, p < 0.001) (Figure 5B). These data, together with the correlation found between the expression of the CDC25A at protein and tumor size, may emphasize the role of these miRNAs in the pathomechanism of NFPA.
To explore biological functions related to miR-424 and miR-503, we performed gene set enrichment analysis of targets of these two miRs predicted by multiple target prediction algorithms using StaRBase miRFunction analysis. Gene ontology categories were determined, and the most significant process affected by these miRNAs was proved to be the “cell cycle” (Table 2). Pathway analysis for miRNA targets revealed that among the three pathways identified “Cell cycle” was also represented, although “Pathways in cancer” signaling was also significant with 20 gene transcripts such as Cyclin E, Cyclin D, FGFR1, BCL2 and MAPK9 (Table 3).

Figure 5. Expression of hsa-miR-424 and -503 (Panel A) and their correlation with tumor size in NFPA samples (Panel B). Both miRs were downregulated in NFPA samples compared to normal pituitary (miR-424: fold change:-45.8 and miR-503: fold change:-35.0; p ≤ 0.001 for both genes) and correlated with tumor size (Pearson Rank correlation: R=-0.89 for miR-424 and R=-0.95 for miR-503; p < 0.001; for both associations). 

Table 2. Gene ontology categories of target genes of miR-424 and miR-503 using StaRBase.
GO ID	GO Term	GO Type	Hypergeometric P-value	Corrected P-value(BF)	Gene Number for Term	Hit Gene Number for Term
GO:0007049	cell cycle	Process	2.40E-06	3.08E-03	409	29
GO:0006468	protein phosphorylation	Process	3.14E-06	4.02E-03	370	27
GO:0032880	regulation of protein localization	Process	2.57E-05	3.30E-02	23	6
GO:0000398	nuclear mRNA splicing, via spliceosome	Process	4.57E-05	5.86E-02	166	15
GO:0000045	autophagic vacuole assembly	Process	4.81E-05	6.17E-02	16	5
 						
hsa-miR-424, hsa-miR-503 target 467 genes that cover 1282 Process terms.		
hsa-miR-424, hsa-miR-503 targets picked 467 (2.702%) of all 17282 genes that having GO terms.
 						





hsa-miR-424, hsa-miR-503 target 467 genes that cover 425 Function terms.		
hsa-miR-424, hsa-miR-503 targets picked 467 (2.702%) of all 17282 genes that having GO terms.
 						







GO:0000307	cyclin-dependent protein kinase holoenzyme complex	Component	5.95E-05	1.68E-02	9	4




hsa-miR-424, hsa-miR-503 target 467 genes that cover 282 Component terms.		
hsa-miR-424, hsa-miR-503 targets picked 467 (2.702%) of all 17282 genes that having GO terms.

Table 3. Pathway analysis of target genes of miR-424 and miR-503 using StaRBase.
KEGG ID	KEGG Term	Hypergeometric P-value	Gene Number for Term	Hit Gene Number for Term	Hit Gene Symbols
hsa04910 (​http:​/​​/​www.genome.ad.jp​/​dbget-bin​/​show_pathway?hsa04910​)	Insulin signaling pathway	0.000282	134	12	PRKAB2, PHKA1, PRKAR1A, PRKACA, PRKAR2A, HK1, GRB2, CRKL, EIF4EBP1, RKAA1, MAPK9, RPS6KB1
hsa05200 (​http:​/​​/​www.genome.ad.jp​/​dbget-bin​/​show_pathway?hsa05200​)	Pathways in cancer	0.000432	318	20	FGFR1, CCNE1, GRB2, TPM3, BCL2, RARB, MAPK9, WNT3A, CDK6, EGLN1, CHUK, CDC42, CCND1, VEGFA, ITGA2, AXIN2, FGF2, CRKL, E2F3, NCOA4




Vast literature data suggest the involvement of dysregulation of cell cycle in the pathogenesis of pituitary adenomas but the complex regulation of the G2/M transition has not been comprehensively evaluated. Our aim was to systematically evaluate the expression of members of G2/M transition [32].
Among the tested genes several proved to be significantly altered between NFPA and normal pituitary. Because our previous finding showed that Wee1, that inactivates CDK1, was downregulated by miRNAs in pituitary adenomas and that Wee1 had an opposite effect on CDC25 phosphatases, we focused on CDC25 phosphatase molecules. The CDC25 protein kinases are important regulators of cell cycle. Three members: CDC25A, CDC25B and CDC25C have been identified in mammals and each isoform possesses different role in regulation of cell cycle. CDC25A was thought to be implicated in the G1/S transition, while CDC25B and CDC25C were considered as mitotic regulators [33-35]. However, later it was found that CDC25A was able to dephosphorylate (activate) the CDK1-Cyclin B complex and, thereby, to promote G2/M transition, while the lack of this activity may delay termination of the cell cycle [36-38]. Overexpression of CDC25A and CDC25B have been considered as oncogenes, their overexpression has been frequently demonstrated in several types of cancer [39].
We found that CDC25A was overexpressed in NFPAs both at mRNA and protein levels, but CDC25C showed overexpression only at mRNA level in pituitary adenoma compared to normal pituitary tissues. This finding is in line with other observations showing a discordant expression of CDC25 phosphatases at mRNA transcript and protein levels. It is therefore possible that dysregulation of CDC25s may occur at transcriptional, posttranscriptional or posttranslational stages [30]. Reviewing data of five different comparative genome hybridization (CGH) studies performed on pituitary adenoma samples regarding chromosomal localizations of CDC25A and CDC25C (3p21, 5q31). Chromosomal gain for these loci was detected only in a small proportion of NFPAs [25-29] suggesting that no gene amplification occurs in the majority of samples. 
We showed that in NFPA samples CDC25A mRNA expression level correlated with Cyclin B, and that CDC25C expression correlated with Cyclin D1 and CDK1. In addition CDK1 in NFPA samples correlated with Cyclin B and Cyclin H (Supplemental Figure 2) suggesting that the whole G2/M transition may be over-activated in NFPA.
CDC25A and CDC25C dephosphorylates CDK1 on Tyrosine-15 (Tyr-15) thereby we used antibodies against total and phosphorylated CDK1 on Tyr-15. CDK1 forms a complex with Cyclin B, the main regulator of G2/M transition and it is phosphorylated (hence inactivated) on Tyr-15 and Threonine-14 (Thr-14) by Wee1 and Myt kinases. In NFPAs, we found elevated CDK1 at protein level by immunohistochemistry. Expression of CDK1 at mRNA level did not differ in NFPA compared to normal pituitary. These results may suggest that posttranscriptional regulation of the CDK1 expression may have a role. Based on literature search we found that CDK1 is experimentally validated target of miR-650, miR-410, miR-24 and miR-16 [40-42]. Of these miRNAs, miR-410 and miR-24 were underexpressed in our previous miRNA array experiment (miR-410: fold change: -76.6, p=0.004; miR-24 fold change: -2.37; p=0.007) [22].
In relation with the posttranscriptional regulation of CDC25A, we identified two underexpressed miRs, miR-424 and miR-503 which may influence CDC25A protein expression through RNA interference. Reviewing literature data regarding miRNA expression profiling studies in pituitary adenoma [43-44] miR-503 and -424 were found to be downregulated in nonfunctioning and gonadotrope adenomas as well [45] but not in GH producing tumors [46-47].
The direct interaction between these miR-503 and miR-424 and the 3’UTR of CDC25A as well as the exact binding sites were previously demonstrated by reporter system [31]. These two miRNAs are encoded at Xq26.3 in a miRNA cluster together with hsa-miR-450a, miR-450b and hsa-miR-542. Importantly, the latter three miRNAs of the cluster were also found to be underexpressed in our previous analysis in NFPA samples compared to normal pituitary [22]. In addition, the expression level of these miRNAs also showed a strong negative correlation with tumor size [22]. Because CDC25A protein but not mRNA expression positively correlated with adenoma size, we may conclude that miR-424 and miR-503 may have a role in the regulation of CDC25A expression in NFPAs (Figure 6).

Figure 6. Schematic presentation of the interaction between members of the G2/M transition of cell cycle in NFPAs. In one hand, overexpressed CDC25A activates CDK1/Cyclin B complex by dephosphorylation which may be linked to downregulation of miRs targeting CDC25A in NFPA and, on the other hand, Wee1 kinase that inactivates the complex is targeted by three overexpressed miRs causing its downregulation  ADDIN REFMGR.CITE (15). These alterations together may be implicated in the accelerated G2/M transition in NFPAs compared to normal pituitary tissues.

Based on GO classification of targets of the two miRNAs, “cell cycle” was the most significant process, which may broaden their potential function. It was observed that inhibition of miR-424 led to increased protein expression of MEK1 and Cyclin E1 without mRNA changes and increased proliferation in human dermal microvascular endothelial cells (HDMECs) [48] while overexpression of miR-424 reduced cell proliferation [49]. Xu et al showed that Chk1 is an experimentally validated target of miR-424 in cervical cancer [50]. They also found that the expression of miR-424 negatively correlated with Chk1 protein levels in both cervical cancer and normal tissues that we could not prove in pituitary tissue. MiR-424 correlated positively with poor tumor differentiation, advanced clinical stage and lymph node metastasis [50]. It was found that overexpression of miR-424 inhibited cell growth by enhancing apoptosis and by blocking G1/S transition. Our findings showed correlation between the expression loss of these miRNAs and tumor size and overexpression of CDC25A and its correlation with tumor size in NFPA samples further supports the role of these miRNAs in the pathogenesis of NFPA. Beyond the effect on dividing cell, miR-424 has been implied in cell differentiation/maturation in the monocyte-macrophage lineage [51-52]. MiR-503 was also able to induce G1 arrest and decreased proliferation rate in hepatocellular carcinoma cell line [53]. It reduced the number of cells in S phase and inhibited cell growth in human head and neck carcinoma cell line [54]. 
Therapeutical strategies against CDC25 was tested in liver cancer and breast cancer, showing that lowering the CDC25 level induced cell cycle arrest at G2/M [55] and in HER2-positive breast cancer patients the CDC25A overexpression associated with very aggressive phenotype and affected the trastuzumab-combined therapy responsive-rate [56]. However CDC25 inhibitors are investigated in malignant neoplasms their application should be considered in pituitary adenoma cases as well when surgery could not lead to complete removal in order to prevent adenoma expansion. 
To our best knowledge this is the first report systematically investigating G2M transition and reporting CDC25 alteration in NFPA. However, several limitations of our study should be mentioned. Due to the availability of sample specimens and small specimen sizes obtained from surgical removal we could not provide all measurements performed on all samples. This resulted discrepancies in sample numbers used in different experiments. Because of the same reason and due to that immunohistochemistry cannot be performed on fresh frozen specimens we had to use different normal pituitary controls and sometimes different samples for the RNA and for the immunohistochemistry studies. Also, in many cases clinical data were not available that led to the relatively small sample number in correlations with tumor size. All these factors are indicated and can be followed in Table 1.
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